Advanced search
Publication Cover
Therapeutic Delivery Volume 3, 2012 - Issue 6
Submit an article Journal homepage
396
Views
0
CrossRef citations to date
0
Altmetric
Review

Overview and Outlook of Toll-like Receptor ligand–antigen Conjugate Vaccines

Yoshio Fujitab Faculty of Pharmaceutical Sciences Suzuka University of Medical Science 3500-3 [email protected]
&
Hiroaki Taguchia Faculty of Pharmaceutical Sciences Suzuka University of Medical Science 3500-3 Minami-TamagakiSuzuka513-8670MIEJapan
Pages 749-760 | Published online: 01 Jun 2012

References

  • Tognotti E . The eradication of smallpox, a success story for modern medicine and public health: what lessons for the future? J. Infect. Dev. Ctries4(5), 264–266 (2010).
  • Cima G . Rinderpest eradicated. International organizations declare ‘cattle plague‘ dead. J. Am. Vet. Med. Assoc.239(1), 11–15 (2011).
  • Roberts L . Polio eradication. Looking for a little luck. Science323(5915), 702–705 (2009).
  • Aylward B , YamadaT. The polio endgame. N. Engl. J. Med.364(24), 2273–2275 (2011).
  • Zauner W , LingnauK, MatterF, von Gabain A, Buschle M. Defied synthetic vaccines. Biol. Chem.382(4), 581–595 (2001).
  • Pashine A , ValianteNM, UlmerJB. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med.11(4), S63–S68 (2005).
  • Aguilar JC , RodfíguezEG. Vaccine adjuvants revisited. Vaccine25(19), 3752–3762 (2007).
  • Guy B . The perfect mix: recent progress in adjuvant research. Nat. Rev. Micro.5(7), 505–517 (2007).
  • Imler JL , HoffmannJA. Signaling mechanisms in the antimicrobial host defense of Drosophila. Curr. Opin. Microbiol.3(1), 16–22 (2000).
  • Aderem A , UlevitchRJ. Toll-like receptors in the induction of the innate immune response. Nature406(6797), 782–787 (2000).
  • Medzhitov R . Toll-like receptors and innate immunity. Nat. Rev. Immunol.1(2), 135–145 (2001).
  • Kumar H , KawaiT, AkiraS. Toll-like receptors and innate immunity. Biochem. Biophys. Res. Commun.388(4), 621–625 (2009).
  • Takeda K , KaishoT, AkiraS. Toll-like receptors. Annu. Rev. Immunol.21, 335–376 (2003).
  • Uematsu S , JangMH, ChevrierNet al. Detection of pathogenic intestinal bacteria by Toll-like receptor 5 on intestinal CD11c+ lamina propria cells. Nat. Immunol. 7(8), 868–874 (2006).
  • Zhang D , ZhangG, HaydenMSet al. A Toll-like receptor that prevents infection by uropathogenic bacteria. Science 303(5663), 1522–1526 (2004).
  • Akira S , TakedaK. Toll-like receptor signaling. Nat. Rev. Immunol.4(7), 499–511 (2004).
  • Sun J , WiklundF, ZhengSLet al. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J. Natl Cancer Inst. 97(7), 525–532 (2005).
  • Bochud PY , HersbergerM, TafféPet al. Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. AIDS 21(4), 441–446 (2007).
  • Sobieszczyk ME , LingappaJR, McElrathMJ. Host genetic polymorphisms associated with innate immune factors and HIV-1. Curr. Opin. HIV AIDS6(5), 427–434 (2011).
  • Hawn TR , ScholesD, LiSSet al. Toll-like receptor polymorphisms and susceptibility to urinary tract infections in adult women. PLoS ONE 4(6), e5990 (2009).
  • Johnson CM , LyleEA, OmuetiKOet al. Cutting edge: a common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against Leprosy. J. Immunol. 178(12), 7520–7524 (2007).
  • Misch EA , MacdonaldM, RanjitCet al. Human TLR1 deficiency is associated with impaired mycobacterial signaling and protection from Leprosy reversal reaction. PLoS Negl. Trop. Dis. 2(5), e231 (2008).
  • Schroder NW , DiterichI, ZinkeAet al. Heterozygous Arg753Gln polymorphism of human TLR-2 impairs immune activation by Borrelia burgdorferi and protects from late stage Lyme disease. J. Immunol. 175(4), 2534–2540 (2005).
  • Hawn TR , VerbonA, LettingaKDet al. A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to Legionnaires‘ Disease. J. Exp. Med. 198(10), 1563–1572 (2003).
  • Hawn TR , VerbonA, JanerM, ZhaoLP, BeutlerB, AderemA. Toll-like receptor 4 polymorphisms are associated with resistance to Legionnaires‘ disease. Proc. Natl Acad. Sci. USA102(7), 2487–2489 (2005).
  • Zhang Q , QianFH, ZhouLFet al. Polymorphisms in Toll-like receptor 4 gene are associated with asthma severity but not susceptibility in a Chinese Han population. J. Investig. Allergol. Clin. Immunol. 21(5), 370–377 (2011).
  • Kanagaratham C , CamaterosP, FlaczykA, RadziochD. Polymorphisms in Toll-like receptor genes and their roles in allergic asthma and atopy. Recent Pat. Inflamm. Allergy Drug Discov.5(1), 45–56 (2011).
  • Wurfel MM , GordonAC, HoldenTDet al. Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsis. Am. J. Respir. Crit. Care Med. 178(7), 710–720 (2008).
  • Ma X , LiuY, GowenBB, GravissEA, ClarkAG, MusserJM. Full-exon resequencing reveals Toll-like receptor variants contribute to human susceptibility to tuberculosis disease. PLoS One2(12), e1318 (2007).
  • Hawn TR , MischEA, DunstanSJet al. A common human TLR1 polymorphism regulates the innate immune response to lipopeptides. Eur. J. Immunol. 37(8), 2280–2289 (2007).
  • Arbour NC , LorenzE, SchutteBCet al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet. 25(2), 187–191 (2000).
  • Pinto A , MorelloS, SorrentinoR. Lung cancer and Toll-like receptors. Cancer Immunol. Immunother.60(9), 1211–1220 (2011).
  • Wang H , RayburnE, ZhangR. Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosinedinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics. Curr. Pharm. Des.11(22), 2889–2907 (2005).
  • Akazawa T , InoueN, ShimeH, KodamaK, MatsumotoM, SeyaT. Adjuvant engineering for cancer immunotherapy development of a synthetic TLR2 ligand with increased cell adhesion. Cancer Sci.101(7), 1596–1603 (2010).
  • Johansen P , SentiG, Martinez Gomez JM et al. Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy. Clin. Exp. Allergy35(12), 1591–1598 (2005).
  • Metzger JW , Beck-SickingerAG, LoleitM, EckertM, BesslerWG, JungG. Synthetic S-(2,3-dihydroxypropyl)-cysteinyl peptides derived from the N-terminus of the cytochrome subunit of the photoreaction centre of Rhodopseu-domonasviridis enhance murine splenocyte proliferation. J. Pept. Sci.1(3), 184–190 (1995).
  • Langhan B , BraunschweigerI, SchweitzerSet al. Lipidation of T helper sequences from hepatits C virus core significantly enhances T-cell activity in vitro. Immunol.102(4), 460–465 (2001).
  • Sieling PA , ChungW, DuongBT, GodowskiPJ, ModlinRL. Toll-like receptor 2 ligands as adjuvants for human Th1 responses. J. Immunol.170(1), 194–200 (2003).
  • Takeda K , AkiraS. Microbial recognition by Toll-like receptors. J. Dermatol. Sci.34(2), 73–82 (2004).
  • Sacht G , MärtenA, DeitersUet al. Activation of nuclear factor-κB in macrophages by mycoplasmal lipopeptides. Eur. J. Immunol. 28(12), 4207–4212 (1998).
  • Muhlradt PF , KiessM, MeyerH, SussmuthR, JungG. Structure and specific activity of macrophage-stimulating lipopeptides from Mycoplasma hyorhinis. Infect. Immun.66(10), 4804–4810(1998).
  • Muhlradt PF , KiessM, MeyerH, SussmuthR, JungG. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J. Exp. Med.185(11), 1951–1958 (1997).
  • Jackson DC , LauYF, LeTet al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc. Natl Acad. Sci. USA 101(43), 15440–15445 (2004).
  • Zeng W , ErikssonE, ChuaB, GrolloL, JacksonDC. Structural requirement for the agonist activity of the TLR2 ligand Pam2Cys. Amino Acids39(2), 471–480 (2010).
  • Abdel-Aal A -BM, Al-Isae K, Zaman M, Toth I. Simple synthetic Toll-like receptor 2 ligands. Bioorg. Med. Chem. Lett.21(24), 5863–5865 (2011).
  • Seyberth T , VossS, BrockP, Wiesmüller K-H, Jung G. Lipolanthionine peptides act as inhibitors of TLR2-mediated IL-8 secretion. Synthesis and structure-activity relationships. J. Med. Chem.49(5), 1754–1765 (2006).
  • Wu W , LiR, MalladiSSet al. Structure–activity relationships in Toll-like receptor-2 agonistic diacylthioglycerol lipopeptides. J. Med. Chem. 53(8), 3198–3213 (2010).
  • Jin MS , KimSE, HeoJYet al. Crystal structure of the TLR1–TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 130(6), 1071–1082 (2007).
  • Zeng W , GhoshS, LauYF, BrownLE, JacksonDC. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J. Immunol.169(9), 4905–4912 (2002).
  • Lau YF , DeliyannisG, ZengW, MansellA, JacksonDC, BrowLE. Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines. Int. Immunol.18(12), 1801–1813 (2006).
  • Hewitt MC , SeebergerPH. Solution and solid-support synthesis of a potential leishmaniasis carbohydrate vaccine. J. Org. Chem.66(12), 4233–4243 (2001).
  • Buskas T , ThompsonP, BoonsGJ. Immunotherapy for cancer: synthetic carbohydrate-based vaccines. Chem. Commun. (Camb.)36, 5335–5349 (2009).
  • Ingale S , WolfertMA, BuskasT, Boons G-J. Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors. Chem. Bio. Chem.10(3), 455–463 (2009).
  • Ingale S , WolfertMA, GaewadJ, BuskasT, Boons G-J. Robust immune responses elicited by a fully synthetic three-component vaccine. Nat. Chem. Biol.3(10), 663–667 (2007).
  • Kaiser A , GaidzikN, BeckerTet al. Fully synthetic vaccines consisting of tumor-associated MUC1 glycopeptides and a lipopeptide ligand of the Toll-like receptor 2. Angew. Chem. Int. Ed. 49(1), 1–6 (2010).
  • Cai H , HuangZH, ShiL, ZhaoYF, KunzH, LiYM. Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry. Chemistry17(23), 6396–6406 (2011).
  • Hollingsworth MA , SwansonBJ. Mucins in cancer: protection and control of the cell surface. Nat. Rev. Cancer4(1), 45–60 (2004).
  • Moyle PM , TothI. Self-adjuvanting lipopeptide vaccines. Curr. Med. Chem.15(5), 506–516 (2008).
  • Zaman M , Abdel-AalAB, PhillippsKS, FujitaY, GoodMF, TothI. Structure-activity relationship of lipopeptide group A streptococcus (GAS) vaccine candidates on Toll-like receptor 2. Vaccine28(10), 2243–2248 (2010).
  • Zaman M , Abdel-AalAB, FujitaYet al. Immunological evaluation of lipopeptide group A streptococcus (GAS) vaccine: structure–activity relationship. PLoS One 7(1), e30146 (2012).
  • Abdel-Aal AB , ZamanM, FujitaY, BatzloffMR, GoodMF, TothI. Design of three-component vaccines against group A streptococcal infections: importance of spatial arrangement of vaccine components. J. Med. Chem.53(22), 8041–8046 (2010).
  • Beutler B . Endotoxin, Toll-like receptor 4, and the afferent limb of innate immunity. Curr. Opin. Microbiol.3(1), 23–28 (2000).
  • Ulevitch RJ . Recognition of bacterial endotoxins by receptor-dependent mechanisms. Adv. Immunol.53, 267–289 (1993).
  • Allison AC . Adjuvants and immune enhancement. Int. J. Technol. Assess. Health Care10(1), 107–120 (1994).
  • Park BS , SongDH, KimHM, Choi B-S, Lee H, Lee J-O. The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex. Nature458(7242), 1191–1195 (2009).
  • Qureshi N , MascagniP, RibiE, TakayamaK. Monophosphoryl lipid A obtained from lipopolysaccharides of Salmonella minnesota R595: purification of the dimethyl derivative by high performance lipid chromatography and complete structural determination. J. Biol. Chem.260(9), 5271–5278 (1985).
  • Myers K , TrochotAT, WardJ. A critical determination of lipid A endotoxic activity. Cellular and molecular aspects of endotoxin reactions. Proceedings of the 1st Congress of the International Endotoxin Society. San Diego, USA, 9–12 May 1990.
  • Wang Q , XueJ, GuoZ. Synthesis of a monophosphoryl lipid A derivative and its conjugation to a modified form of a tumor-associated carbohydrate antigen GM3. Chem. Commun. (Camb.)37, 5536–5537 (2009).
  • Wang Q , ZhouZ, TangS, GuoZ. Carbohydrate–monophosphoryl lipid A conjugates are fully synthetic self-adjuvanting cancer vaccines eliciting robust immune responses in the mouse. ACS Chem. Biol.7(1), 235–240 (2012).
  • Gewirtz AT , NavasTA, LyonsS, GodowskiPJ, MadaraJL. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J. Immunol.167(4), 1882–1885 (2001).
  • Hayashi F , SmithKD, OzinskyAet al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410(6832), 1099–1103 (2001).
  • Huleatt JW , JacobsAR, TangJet al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 25(4), 763–775 (2007).
  • Bargieri DY , RosaDS, BragaCJet al. New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella typhimurium FliC flagellin. Vaccine 26(48), 6132–6142 (2008).
  • Braga CJ , MassisLM, Sbrogio-AlmeidaMEet al. CD8+ T cell adjuvant effects of Salmonella FliCd flagellin in live vaccine vectors or as purified protein. Vaccine 28(5), 1373–1382 (2010).
  • Delaney KD , PhippsJP, JohnsonJB, MizelSB. A recombinant flagellin–poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice. Viral Immunol.23(2), 201–210(2010).
  • Lamb RA , LaiCJ, ChoppinPW. Sequences of mRNAs derived from genome RNA segment 7 of influenza virus: colinear and interrupted mRNAs code for overlapping proteins. Proc. Natl Acad. Sci. USA78(7), 4170–4174 (1981).
  • Fiers W , De Filette M, El Bakkouri K et al. M2e-based universal influenza A vaccine. Vaccine27(45), 6280–6283 (2009).
  • Huleatt JW , NakaarV, DesaiPet al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26(2), 201–214 (2008).
  • Talbot HK , RockMT, JohnsonCet al. Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin. PLoS One 5(12), e14442 (2010).
  • Turley CB , RuppRE, JohnsonCet al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 29(32), 5145–5152 (2011).
  • Song L , NakaarV, KavitaUet al. Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. PLoS ONE 3(5), e2257 (2008).
  • Song L , ZhangY, YunNEet al. Superior efficacy of a recombinant flagellin: H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin. Vaccine 27(42), 5875–5884 (2009).
  • Treanor JJ , TaylorDN, TusseyLet al. Safety and immunogenicity of a recombinant hemagglutinin influenza–flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine 28(52), 8268–8274 (2010).
  • Taylor DN , TreanorJJ, StroutCet al. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). Vaccine 29(31), 4897–4902 (2011).
  • Gerster JF , LindstromKJ, MillerRLet al. Synthesis and structure–activity relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production. J. Med. Chem. 48(10), 3481–3491 (2005).
  • Tomai MA , GibsonSJ, ImbertsonLMet al. Immunomodulating and antiviral activities of the imidazoquinolines S-28463. Antiviral Res. 28(3), 253–264 (1995).
  • Izumi T , SakaguchiJ, TakeshitaMet al. 1H-Imidazo[4,5-c]quinoline derivatives as novel potent TNF-alpha suppressors: synthesis and structure-activity relationship of 1-, 2-and 4-substituted 1H-imidazo[4,5-c]quinolines or 1H-imidazo[4,5-c]pyridines. Bioorg. Med. Chem. 11(12), 2541–2550 (2003).
  • Miller RL , GersterJF, OwensML, SladeHB, TomaiMA. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int. J. Immunopharmacol.21(1), 1–14 (1999).
  • Shukla NM , KimbrellMR, MalladiSS, DavidSA. Regioisomerism-dependent TLR7 agonism and antagonism in an imidazoquinoline. Bioorg. Med. Chem. Lett.19(8), 2211–2214 (2009).
  • Shukla NM , MalladiSS, DayV, DavidSA. Preliminary evaluation of a 3H-imidazoquinoline library as dual TLR7/TLR8 antagonists. Bioorg. Med. Chem.19(12), 3801–3811 (2011).
  • Shukla NM , MalladiSS, MutzCA, BalakrishnaR, DavidSA. Structure–activity relationships in human Toll-like receptor 7-active imidazoquinoline analogues. J. Med. Chem.53(11), 4450–4465 (2010).
  • Shukla NM , MutzCA, UkaniR, WarshakoonHJ, MooreDS, DavidSA. Syntheses of fluorescent imidazoquinoline conjugates as probes of Toll-like receptor 7. Bioorg. Med. Chem. Lett.20(22), 6384–6386 (2010).
  • Wille-Reece U , WuCY, FlynnBJ, KedlRM, SederRA. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T Cell responses. J. Immunol.174(12), 7676–7683 (2005).
  • Wille-Reece U , FlynnBJ, LoréKet al. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+T cell responses in nonhuman primates. Proc. Natl Acad. Sci. USA 102(42), 15190–15194 (2005).
  • Wille-Reece U , FlynnBJ, LoréKet al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J. Exp. Med. 203(5), 1249–1258 (2006).
  • Oh JZ , KurcheJS, BurchillMA, KedlRM. TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway. Blood118(11), 3028–3038 (2011).
  • Shukla NM , LewisTC, DayTPet al. Toward self-adjuvanting subunit vaccines: model peptide and protein antigens incorporating covalently bound Toll-like receptor-7 agonistic imidazoquinolines. Bioorg. Med. Chem. Lett. 21(11), 3232–3236 (2011).
  • Krieg AM . CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol.20, 709–760 (2002).
  • Heit A , SchmitzF, HaasT, BuschDH, WagnerH. Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity. Eur. J. Immunol.37(8), 2063–2074 (2007).
  • Kim D , KwonS, RheeJWet al. Production of antibodies with peptide–CpG-DNA liposome complex without carriers. BMC Immunol. 12, 29 (2011).
  • Häcker H , MischakH, MiethkeTet al. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J. 17(21), 6230–6240 (1998).
  • Raja K , McDonaldR, TuckS, RodriguezR, MilleyB, TraquinaP. One-pot synthesis, purification, and formulation of bionanoparticle–CpG oligodeoxynucleotide hepatitis B surface antigen conjugate vaccine via tangential flow filtration. Bioconjug. Chem.18(2), 285–288 (2007).
  • Heit A , MaurerT, HochreinHet al. Cutting edge: Toll-like receptor 9 expression is not required for CpG DNA-aided cross-presentation of DNA-conjugated antigens but essential for cross-priming of CD8 T cells. J. Immunol. 170(6), 2802–2805 (2003).
  • Sandip K . Datta SK, Cho HJ, Takabayashi K, Horner AA, Raz E. Antigen–immunostimulatory oligonucleotide conjugates: mechanisms and applications. Immunol. Rev.199, 217–226 (2004).
  • Heit A , SchmitzF, O‘KeeffeMet al. Protective CD8 T cell immunity triggered by CpG–protein conjugates competes with the efficacy of live vaccines. J. Immunol. 174(7), 4373–4380 (2005).
  • Khan S , BijkerMS, WeteringsJJet al. Distinct uptake mechanisms but similar intracellular processing of two different Toll-like receptor ligand–peptide conjugates in dendritic cells. J. Biol. Chem. 282(29), 21145–21159 (2007).
  • Teshima R , OkunukiH, SatoY, AkiyamaH, MaitaniT, SawadaJ. Effect of oral administration of CpG ODN on WBB6F1-W/Wv mice. Allergol. Int.55(1), 43–48 (2006).
  • Tulic MK , FisetPO, ChristodoulopoulosPet al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J. Allergy Clin.Immunol. 113(2), 235–241 (2004).
  • Simons FE , ShikishimaY, Van Nest G, Eiden JJ, HayGlass KT. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J. Allergy Clin. Immunol.113(6), 1144–1151 (2004).
  • Creticos PS , SchroederJT, HamiltonRGet al. Immunotherapy with a ragweed-Toll-like receptor 9 agonist vaccine for allergic rhinitis. N. Engl. J. Med. 355(14), 1445–1455 (2006).
  • Rafnar T , GriffithIJ, KuoMC, BondJF, RogersBL, KlapperDG. Cloning of Amba I (antigen E), the major allergen family of short ragweed pollen. J. Biol. Chem.266(2), 1229–1236 (1991).
  • Roelofs MF , JoostenLA, Abdollahi-RoodsazSet al. The expression of Toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of Toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum. 52(8), 2313–2322 (2005).
  • Zhu Q , EgelstonC, VivekanandhanAet al. Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines. Proc. Natl. Acad. Sci. USA. 105(42), 16260–16265 (2008).
  • Zhu Q , EgelstonC, GagnonSet al. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J. Clin. Invest. 120(2), 609–616 (2010).
  • Napolitani G , RinaldiA, BertoniF, SallustoF, LanzavecchiaA. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol.6(8), 769–776 (2005).
  • Warger T , OsterlohP, RechtsteinerGet al. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 108(2), 544–550 (2006).
  • Querec T , BennounaS, AlkanSet al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 203(2), 413–424 (2006).
  • Querec TD , AkondyRSet al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10, 116–125 (2009).
  • Kasturi SP , SkountzouI, AlbrechtRAet al. Programing the magnitude and persistence of antibody responses with immunity. Nature 470(7335), 543–547 (2011).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.